Analytical Data
-
Gene name
COL1A1
- Application
-
Alternative Names
COL-1A1; COL1-A1; COL1A-1; OI4; Collagen Alpha-1(I)chain
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P02452
-
Expression Region
Asp1219~Leu1464
-
Molecular Weight
35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Pro-COL1A1, or pro-alpha1(I) chain of type I collagen, is a crucial extracellular matrix protein that plays a significant role in maintaining the structural integrity of various tissues, particularly in bones and skin. Type I collagen is the most abundant collagen type in mammals and is predominantly found in connective tissues, providing tensile strength and supporting cellular functions. Impaired collagen synthesis or mutations in the COL1A1 gene can lead to severe connective tissue disorders, such as osteogenesis imperfecta and Ehlers-Danlos syndrome. Research into Pro-COL1A1 recombinant proteins is essential for understanding collagen biosynthesis and pathology. Recombinant production of this protein enables the study of its folding, post-translational modifications, and interactions with other extracellular matrix components. Moreover, Pro-COL1A1 serves as a valuable tool in regenerative medicine and tissue engineering, offering insights into potential therapeutic strategies for treating connective tissue disorders. By elucidating the mechanisms underlying collagen assembly and function, researchers aim to develop innovative treatments that might restore collagen-related deficiencies and improve patient outcomes in various fibrotic diseases and injuries.
